High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease
JACC · 2025-12 · 86 (25) · 2636-2647
DOI: 10.1016/j.jacc.2025.10.005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC, 2025-12. Verfasst von Katja Vu Bartholdy und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmati…. Hauptthemen laut MEDLINE: Influenza Vaccines, Renal Insufficiency, Chronic, Influenza, Human. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi US.
Abstract (Originalsprache)
BACKGROUND: Influenza-related complications occur frequently in persons with chronic kidney disease (CKD). Limited data exist on the effectiveness of high-dose inactivated influenza vaccine (HD-IIV) in persons with CKD. OBJECTIVES: The purpose of this study was to assess the relative effectiveness (rVE) of HD-IIV vs standard-dose inactivated influenza vaccine (SD-IIV) against severe clinical outcomes in persons with CKD from the elderly general population. METHODS: DANFLU-2 (A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Influenza Vaccine vs. Standard-Dose Influenza Vaccine in Older Adults) was a pragmatic, open-label, individually randomized trial conducted in Denmark during the 2022-2023, 2023-2024, and 2024-2025 influenza seasons with the aim of assessing the rVE of HD-IIV vs SD-IIV in an older adult general population. In this prespecified secondary analysis, we assessed the rVE against severe clinical outcomes according to the presence of CKD. CKD was defined using data from laboratory registries and International Classification of Diseases-10th Revision diagnosis codes 10 years before vaccination. RESULTS: Among 332,438 DANFLU-2 participants (mean age 73.7 ± 5.8 years; 48.6% women), 46,788 (14.1%) had CKD at baseline. The effect of HD-IIV vs SD-IIV on hospitalization for influenza or pneumonia differed by CKD status: rVE was 16.9% (95% CI: 3.4%-28.5%) in participants with CKD vs 0.6% (95% CI: -9.6% to 9.9%) in those without CKD (P interaction = 0.046). Absolute risks for hospitalization for influenza or pneumonia were 1.7% with SD-IIV vs 1.3% with HD-IIV in CKD, corresponding to an absolute risk reduction of -0.29% (95% CI: -0.50% to 0.058%; number needed to treat [NNT] = 359). For influenza hospitalizations specifically, the benefit of HD-IIV was also substantially greater in CKD: rVE 68.6% (95% CI: 46.7%-82.3%; NNT = 561) vs 30.6% (95% CI: 7.2%-48.2%; NNT =3,953) in non-CKD (P interaction = 0.0079). Reductions in hospitalizations for cardiorespiratory disease, cardiovascular disease, heart failure, and laboratory-confirmed influenza were consistent regardless of CKD (all P interaction > 0.05). CONCLUSIONS: In this prespecified analysis of DANFLU-2, including the largest CKD population ever in an individually randomized vaccine trial, we observed a benefit of HD-IIV vs SD-IIV against hospitalization for influenza or pneumonia, as well as hospitalization for influenza, with suggestion of a greater relative benefit among those with CKD. Furthermore, the beneficial effect of HD-IIV vs SD-IIV on multiple cardiorespiratory outcomes was consistent across participants irrespective of CKD status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark; Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Hea…
- Sanofi, Morristown, New Jersey, USA; Department of Epidemiology, University of Delaware, Newark, Delaware, USA.
- Sanofi, Singapore.
- Sanofi, Lyon, France.
- Department of Clinical Medicine-Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Danske Lægers Vaccinations Service/European LifeCare Group, Søborg, Denmark.
- Department of Infectious Diseases, Odense University Hospital, Odense, Denmark.
Förderung
- Sanofi US
Zitieren
APA
Bartholdy, K. V., Johansen, N. D., Modin, D., Loiacono, M. M., Harris, R. C., Dufournet, M., Larsen, C. S., Larsen, L., Wiese, L., Dalager-Pedersen, M., Claggett, B. L., Bernholm, K. F., Borchsenius, J. I. H., Davidovski, F. S., Davodian, L. W., Dons, M. F., Duus, L. S., Espersen, C., Fussing, F. H., …, & Biering-Sørensen, T. (2025). High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease. JACC, 86(25), 2636-2647. https://doi.org/10.1016/j.jacc.2025.10.005
Vancouver
Bartholdy KV, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, et al. High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease. JACC. 2025;86(25):2636-2647. doi:10.1016/j.jacc.2025.10.005
BibTeX
@article{Bartholdy2025,
author = {Bartholdy, Katja Vu and Johansen, Niklas Dyrby and Modin, Daniel and Loiacono, Matthew M and Harris, Rebecca C and Dufournet, Marine and Larsen, Carsten Schade and Larsen, Lykke and Wiese, Lothar and Dalager-Pedersen, Michael and Claggett, Brian L and Bernholm, Katrine Feldballe and Borchsenius, Julie Inge-Marie Helene and Davidovski, Filip Søskov and Davodian, Lise Witten and Dons, Maria Flarup and Duus, Lisa Steen and Espersen, Caroline and Fussing, Frederik Holme and Jensen, Anne Marie Reimer and Landler, Nino Emanuel and Langhoff, Adam Cadovius Femerling and Lassen, Mats Christian Højbjerg and Nielsen, Anne Bjerg and Ottosen, Camilla Ikast and Sengeløv, Morten and Skaarup, Kristoffer Grundtvig and Solomon, Scott D and Landray, Martin J and Gislason, Gunnar H and Køber, Lars and Sivapalan, Pradeesh and Martel, Cyril Jean-Marie and Jensen, Jens Ulrik Stæhr and Biering-Sørensen, Tor},
title = {High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease},
journal = {JACC},
year = {2025},
volume = {86},
number = {25},
pages = {2636--2647},
doi = {10.1016/j.jacc.2025.10.005}
}
EUVIMED